Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia

Stone, 2010, Pathophysiology of Waldenström’s macroglobulinemia, Haematologica, 95, 359, 10.3324/haematol.2009.017251 Herrinton, 1993, Incidence of Waldenström’s macroglobulinemia, Blood, 82, 3148, 10.1182/blood.V82.10.3148.bloodjournal82103148 Marcelli, 1988, Histologic evidence of an abnormal bone remodeling in B-cell malignancies other than multiple myeloma, Cancer, 62, 1163, 10.1002/1097-0142(19880915)62:6<1163::AID-CNCR2820620620>3.0.CO;2-6 Weidle, 2010, Interleukin 6/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer, Cancer Genomics Proteomics, 7, 287 Poulain, 2008, The IL6(-174G/C) polymorphism is a prognostic factor for survival after treatment initiation in Waldenstrom macroglobulinemia patients aged 65 years or less, Haematologica, 93, 1109, 10.3324/haematol.12530 Terpos, 2003, Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma, Br J Haematol, 123, 106, 10.1046/j.1365-2141.2003.04561.x Spanoudakis, 2016, Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma, Blood Cancer, 11, 6 Terpos, 2014, Management of bone disease in multiple myeloma, Expert Rev Hematol, 7, 113, 10.1586/17474086.2013.874943 Terpos, 2003, Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index, Blood, 102, 1064, 10.1182/blood-2003-02-0380 Terpos, 2011, Expression of CCL3 by neoplastic cells in patients with Waldenström’s macroglobulinemia: an immunohistochemical study in bone marrow biopsies of 67 patients, Clin Lymphoma Myeloma Leuk, 11, 115, 10.3816/CLML.2011.n.024 Terpos, 2006, Abnormal bone remodeling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1α) in Waldenström macroglobulinemia, Br J Haematol, 133, 301, 10.1111/j.1365-2141.2006.06017.x Palma, 2016, Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: role of chemokine (C-C motif) ligand 20, Leukemia, 30, 409, 10.1038/leu.2015.259 Roussou, 2009, Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma, Leukemia, 23, 2177, 10.1038/leu.2009.130 Botta, 2016, A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival, Blood Cancer J, 16, 6 Mazur, 2011, Proinflammatory chemokine gene expression influences survival of patients with non-Hodgkin’s lymphoma, Folia Histochem Cytobiol, 49, 240, 10.5603/FHC.2011.0033 Tedla, 1999, Abundant expression of chemokines in malignant and infective human lymphadenopathies, Cytokine, 11, 531, 10.1006/cyto.1998.0439 Menten, 2002, Role of the autocrine chemokines MIP-1alpha and MIP-1beta in the metastatic behavior of murine T cell lymphoma, J Leukoc Biol, 72, 780, 10.1189/jlb.72.4.780 Hartmann, 2016, CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates, Leuk Lymphoma, 57, 563, 10.3109/10428194.2015.1068308 Zucchetto, 2009, CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival, Cancer Res, 69, 4001, 10.1158/0008-5472.CAN-08-4173 Sivina, 2011, CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia, Blood, 117, 1662, 10.1182/blood-2010-09-307249 Kay, 2016, A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia, Oncotarget, 7, 78269, 10.18632/oncotarget.13412 Kim, 2017, Macrophage inflammatory protein 1 alpha (MIP-1α) may be associated with poor outcome in patients with extranodal NK/T-cell lymphoma, Hematol Oncol, 35, 310, 10.1002/hon.2283 Takahashi, 2015, CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma, Br J Haematol, 171, 726, 10.1111/bjh.13659 Hamed, 2007, Role of CCL3 protein (monocyte inflammatory protein-1 alpha) in lymphoid malignancy, Egypt J Immunol, 14, 63 Elsawa, 2011, Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity, Blood, 118, 5540, 10.1182/blood-2011-04-351742 Menten, 2002, Macrophage inflammatory protein-1, Cytokine Growth Factor Rev, 13, 455, 10.1016/S1359-6101(02)00045-X Seymour, 1995, Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma, J Clin Oncol, 13, 575, 10.1200/JCO.1995.13.3.575 Chang, 2013, Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy, Int J Cancer, 132, 1977, 10.1002/ijc.27892 Elsawa, 2007, Role of CCL5 and interleukin-6 in the biology of Waldenström macroglobulinemia, Blood, 110 Leleu, 2007, The Akt pathway regulates survival and homing in Waldenström macroglobulinemia, Blood, 110, 4417, 10.1182/blood-2007-05-092098 da Silva, 2017, Relevance of CCL3/CCR5 axis in oral carcinogenesis, Oncotarget, 8, 51024, 10.18632/oncotarget.16882 Shibata, 2005, Malignant B-Lymphoid cells with bone lesions express receptor activator of nuclear factor-κB ligand and vascular endothelial growth factors to enhance osteoclastogenesis, Clin Cancer Res, 11, 6109, 10.1158/1078-0432.CCR-05-0181 Quattrini, 2015, Prognostic role of nuclear factor/IB and bone remodeling proteins in metastatic giant cell tumor of bone: a retrospective study, J Orthop Res, 33, 1205, 10.1002/jor.22873 Wang, 2016, Clinical prognostic significance and pro-metastatic activity of RANK/RANKL via the AKT pathway in endometrial cancer, Oncotarget, 7, 5564, 10.18632/oncotarget.6795 Bago-Horvath, 2014, Impact of RANK signaling on survival and chemotherapy response in osteosarcoma, Pathology, 46, 411, 10.1097/PAT.0000000000000116 Mueller, 2012, Emerging functions of RANKL in lymphoid tissues, Front Immunol, 3, 261, 10.3389/fimmu.2012.00261 Faget, 2018, RANKL signaling sustains primary tumor growth in genetically engineered mouse models of lung adenocarcinoma, J Thorac Oncol, 13, 387, 10.1016/j.jtho.2017.11.121 Oyajobi, 2003, Dual effects of macrophage inflammatory protein-1 alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease, Blood, 102, 311, 10.1182/blood-2002-12-3905 Tsubaki, 2007, Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways, Mol Cell Biochem, 304, 53, 10.1007/s11010-007-9485-7 Cathomas, 2015, RANK ligand blockade with denosumab in combination with sorafenib in chemorefractory osteosarcoma: a possible step forward?, Oncology, 88, 257, 10.1159/000369975 Chen, 2015, RANKL blockade prevents and treats aggressive osteosarcomas, Sci Transl, 7, 317ra197, 10.1126/scitranslmed.aad0295 de Groot, 2018, The anti-tumor effect of RANKL inhibition in malignant solid tumors—a systematic review, Cancer Treat Rev, 62, 18, 10.1016/j.ctrv.2017.10.010 Kitamura, 2015, Therapeutic potential of chemokine signal inhibition for metastatic breast cancer, Pharmacol Res, 100, 266, 10.1016/j.phrs.2015.08.004